[A clinical observational study on the preliminary effect of dupilumab in the treatment of severe asthma].

医学 杜皮鲁玛 哮喘 内科学 恶化 观察研究 不利影响 临床试验 精确检验 曼惠特尼U检验
作者
Yanping Li,Haiqing Lin,X X Zhang,Changxing Ou,Jiaxing Xie,Q L Zhang
出处
期刊:PubMed [National Institutes of Health]
卷期号:46 (9): 909-915
标识
DOI:10.3760/cma.j.cn112147-20230713-00374
摘要

Objective: To investigate the effect and safety of dupilumab in the treatment of patients with severe asthma in a preliminary clinical observational study. Methods: This study retrospectively analyzed the clinical data of 20 patients with severe asthma who received dupilumab for 4-12 months between 2019 and 2022 at the First Hospital of Guangzhou Medical University, comparing pre-and post-treatment laboratory data, oral glucocorticoid dose (OCS), asthma control test (ACT) and adverse effects. The median age of the 20 patients was 48.5 (41.0-52.8) years, including 14 males and 6 females. The clinical data of 10 patients treated with other biologic agents were further analyzed to determine the reasons for switching to biologic drug treatment and the efficacy of dupilumab in these patients. Paired t-tests or Wilcoxon signed-rank tests were used for comparisons. Mann-Whitney analysis was used for inter-group comparison, and chi-square test or Fisher test was used for inter-group comparisons of count data. Results: A total of 20 patients were included in this study. All 20 severe asthma phenotypes were type 2 (T2)-high and completed at least the first 4 months of treatment, including 17 patients who completed 12 months of treatment. Among patients who completed 4 months of treatment, the asthma exacerbation score decreased from 1.0(0.3-1.0) episodes/4 months to 0.0(0.0-1.0) episodes/4 months, P<0.001, and FEV1/FVC increased from 58.4% (50.5%-69.0%) to 66.9% (59.6%-77.7%), P<0.01. The number of patients requiring OCS maintenance therapy decreased from 15 (75%) to 9 (45%), P<0.05. Among patients who completed 12 months of treatment, the asthma exacerbation score decreased from 1.0(0.5-1.0) episodes/4 months to 0.0 (0.0-0.0) episodes/4 months, P<0.01, and FEV1/FVC increased from 57.9% (49.6%-67.8%) to 72.7% (64.6%-78.7%), P<0.01. The number of patients requiring OCS maintenance therapy decreased from 13 (76%) to 6 (35%), P<0.01. In 10 patients with a history of previous biologic therapy, the most common reasons for switching to a biologic were a poor response to previous monoclonal antibodies (40%) and loss of control of asthma symptom control after discontinuation of monoclonal antibodies (30%). The remaining reasons were patients' uncontrolled symptoms of chronic rhinosinusitis (20%) and irregular or underdosed use of previous biologics (10%). After 4 months of switching to dupilumab, 10 patients experienced varying degrees of improvement in asthma control. Conclusions: The application of dupilumab for the treatment of T2-high severe asthma showed good efficacy and few adverse effects. Biologically targeted therapy is an important treatment approach to achieving better control of severe asthma.目的: 初步观察度普利尤单抗治疗重度哮喘患者的有效性及安全性。 方法: 回顾性分析广州医科大学附属第一医院于2019—2022年接受度普利尤单抗治疗4~12个月的20例重度哮喘患者的临床资料,其中男14例,女6例,中位年龄48.5(41.0,52.8)岁。对比分析其治疗前后支气管哮喘症状控制评分(ACT)、实验室数据、口服糖皮质激素(OCS)剂量以及不良反应等数据,对10例曾使用其他生物制剂治疗的患者进一步研究,分析更换生物制剂的原因及度普利尤单抗对其疗效。两两前后比较采用配对t检验或非参数配对Wilcoxon分析,组间比较用非参数独立样本 Mann-Whitney分析,计数资料组间比较采用卡方检验或 Fisher检验分析。 结果: 共20例患者纳入本研究,均为2型炎症表型且至少接受前4个月治疗,其中17例完成12个月治疗。完成4个月治疗后,对比基线,哮喘急性发作次数由1.0(0.3,1.0)次/4个月降至0.0(0.0,1.0)次/4个月,P<0.001;FEV1/FVC由58.4%(50.5%,69.0%)升至66.9%(59.6%,77.7%),P<0.01;需OCS维持治疗的患者由15例(75%)降至9例(45%),P<0.05。完成12个月治疗后,对比基线,哮喘急性发作次数由1.0(0.5,1.0)次/4个月降至0.0(0.0,0.0)次/4个月,P<0.01;FEV1/FVC由57.9%(49.6%,67.8%)升至72.7%(64.6%,78.7%),P<0.01;需OCS维持治疗由13例(76%)降至6例(35%),P<0.01。对10例有生物制剂治疗史的患者分析,发现导致其更换生物制剂最多的原因是对单抗应答不佳(40%)以及停用单抗后哮喘失去控制(30%),其余原因是慢性鼻-鼻窦炎无法控制(20%)以及生物制剂不足剂量使用(10%),10例患者更换为度普利尤单抗4个月后哮喘控制水平有不同程度提升。 结论: 应用度普利尤单抗治疗2型炎症表型的重度哮喘,初步观察疗效良好,不良反应少。生物靶向治疗是使重度哮喘得到良好控制的重要手段。.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Alice完成签到,获得积分10
刚刚
1秒前
张毛毛完成签到,获得积分10
1秒前
blingbling发布了新的文献求助10
1秒前
2秒前
jhgg8009完成签到,获得积分10
3秒前
一味地丶逞强完成签到,获得积分10
3秒前
神秘剧发布了新的文献求助10
4秒前
宋SY_Progress完成签到,获得积分20
5秒前
Eric的应助被单薄冰安采纳,获得30
5秒前
Hello的应助被777采纳,获得10
6秒前
6秒前
momo完成签到,获得积分20
8秒前
9秒前
xxxx完成签到 ,获得积分10
10秒前
现代雪晴发布了新的文献求助10
10秒前
jhgg8009发布了新的文献求助10
11秒前
momo发布了新的文献求助10
11秒前
12秒前
13秒前
04d的应助被爱学习的doge采纳,获得10
14秒前
huihuiwang完成签到,获得积分10
15秒前
徐徐睡不醒完成签到 ,获得积分10
17秒前
17秒前
wg发布了新的文献求助10
17秒前
18秒前
somehow完成签到,获得积分10
19秒前
20秒前
积极向上完成签到,获得积分10
22秒前
mumu0203发布了新的文献求助30
22秒前
23秒前
宋SY_Progress关注了科研通微信公众号
24秒前
O3O发布了新的文献求助10
24秒前
首负完成签到,获得积分10
25秒前
Emily完成签到 ,获得积分20
25秒前
红宝石设计局完成签到,获得积分10
26秒前
cjh发布了新的文献求助10
26秒前
Hhhh完成签到,获得积分10
29秒前
29秒前
SciGPT的应助被blingbling采纳,获得10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188371
求助须知:如何正确求助?哪些是违规求助? 9576179
关于积分的说明 21845965
捐赠科研通 7786421
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559601
邀请新用户注册赠送积分活动 2482276